Secondary Logo

Journal Logo

Bartlett John
JAIDS Journal of Acquired Immune Deficiency Syndromes: January 2016
doi: 10.1097/01.qai.0000479579.14883.2e
Abstract: PDF Only

Presentation goal: Review of topics important to HIV management that are not commonly discussed Rating the evidence: The “when to start” controversy with the United States versus the rest of the world 2012–2015. The “START trial” provided a definitive answer with an OR of 1.9 for survival! The Gardner cascade: This highlighted our inept care delivery, but the oft quoted cascade is wrong Immune activation: An important message for all of medicine but we don't know how to measure it, or treat it New ART: The new integrase inhibitors radically changed all guidelines to make ART recommendations before 2015 antiquated. Most exciting new drug might might be cenicriviroc (GSK 744) with a T1/2 of 21–50 days When to start debate: Simply said-” it's never too early” HPTN 065 (P4P4P): The first major P4P4P to lose is now explained. PrEP, Bridge, on-demand… and why not Murray and money HIV Prevention: ART (?perfect), ABC/3TC HCV: Miracle.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.